A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

Contacts

Amgen Call Center

CONTACT

866-572-6436 medinfo@amgen.com

Sponsors

Lead Sponsor

Amgen

Collaborators

AstraZeneca

Age

18 - 99 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Participant has provided informed consent before initiation of any study-specific activities/procedures.
•Age ≥ 18 years or ≥ legal age within the country if it is older than 18 years.
•Histologically or cytologically documented ES-SCLC (American Joint Committee on Cancer, 2017, Stage IV SCLC \[T any, N any, M1 a/b/c\]), or T3 to T4 due to multiple lung nodules that are too extensive or have tumor/nodal volume that is too large to be encompassed in a tolerable radiation plan.
•Measurable disease as defined per RECIST 1.1.
•Suitable to receive carboplatin, etoposide and durvalumab regimen as first-line treatment per investigator clinical assessment.
•Minimum life expectancy ≥ 12 weeks.

Exclusion Criteria

•Participants can have no history of other malignancy in the last 2 years.
•Any symptomatic central nervous system (CNS) metastases, or leptomeningeal disease.
•They will have no history of severe or life-threatening events to immune-mediated therapy.
•History of arterial thrombosis (eg, stroke or transient ischemic attack) within 6 months prior to first dose of study treatment.
•They will have no active autoimmune or inflammatory disorders.
•Presence of active human immunodeficiency virus (HIV) or active Hepatitis (B/C) infection.
•Evidence or interstitial lung disease (ILD) or active, non-infectious pneumonitis.
•History of solid organ transplant.
•They will not have had a myocardial infarction and/or symptomatic congestive heart failure (New York Heart Association \> class II) within 6 months prior to first dose of study treatment.

Related studies

RECRUITINGPhase 1/2

A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors

NCT04895709 · Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma, and more

RECRUITING

Durvalumab Consolidation After Chemoradiation Therapy for Limited Stage SCLC in China

NCT07161388 · Limited Stage Small-Cell Lung Cancer

RECRUITINGPhase 2

Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations

NCT07336732 · Non-Small-Cell Lung Cancer

RECRUITINGPhase 1/2

A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors

NCT06747585 · Squamous Non-small-cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, and more

RECRUITINGPhase 3

Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

NCT06712355 · Extensive-stage Small-cell Lung Cancer

View all related studies →

A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

What this study is about

Clareo turns complex medical information into clear understanding you can use.

Contacts

Sponsors

Related studies

A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors

Durvalumab Consolidation After Chemoradiation Therapy for Limited Stage SCLC in China

Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations

A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors

Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

Trial snapshot

Condition

Locations shown

For caregivers